Literature DB >> 15456335

Antiepileptic drugs in the treatment of anxiety disorders: role in therapy.

Michael Van Ameringen1, Catherine Mancini, Beth Pipe, Mark Bennett.   

Abstract

Pharmacotherapy for anxiety disorders is an active area of research. A variety of drug groups have been shown to be effective in treating many of the anxiety disorders, with selective serotonin reuptake inhibitors (SSRIs) being considered first-line agents for virtually all anxiety disorders. There is a clinical need for alternative drug treatments, as many patients do not achieve a complete response and experience significant adverse effects. The successful use of antiepileptic drugs in mood disorders has led clinicians and researchers to investigate their potential efficacy in other psychiatric disorders, particularly in anxiety disorders. There have been a number of investigations conducted in the form of case reports, case series and open-label trials, suggesting the potential usefulness of antiepileptic drug treatment in a variety of anxiety disorders. More reliable evidence for the use of antiepileptic drugs in anxiety disorders can be gleaned from recent placebo-controlled trials. Thus far, the strongest placebo-controlled evidence has demonstrated the efficacy of pregabalin in treating social phobia and generalised anxiety disorder, while smaller or less robust controlled trials have suggested the potential efficacy of gabapentin in social phobia, lamotrigine in post-traumatic stress disorder, and valproic acid in panic disorder. Antiepileptic drugs may have a place in the treatment of anxiety disorders; however, further investigation is warranted to determine in what circumstances they should be used as monotherapy or as augmenting agents in individuals who are partially or non-responsive to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456335     DOI: 10.2165/00003495-200464190-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  104 in total

Review 1.  Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

Authors:  S H Kennedy; R W Lam; N L Cohen; A V Ravindran
Journal:  Can J Psychiatry       Date:  2001-06       Impact factor: 4.356

2.  Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.

Authors:  G Corá-Locatelli; B D Greenberg; J Martin; D L Murphy
Journal:  J Clin Psychiatry       Date:  1998-09       Impact factor: 4.384

3.  Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study.

Authors:  K M Connor; S M Sutherland; L A Tupler; M L Malik; J R Davidson
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

Review 4.  The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.

Authors:  K N Chengappa; S Gershon; J Levine
Journal:  Bipolar Disord       Date:  2001-10       Impact factor: 6.744

5.  Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.

Authors:  M A Rynn; L Siqueland; K Rickels
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

6.  Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.

Authors:  P N Dannon; Y Sasson; S Hirschmann; I Iancu; L J Grunhaus; J Zohar
Journal:  Eur Neuropsychopharmacol       Date:  2000-05       Impact factor: 4.600

Review 7.  Neurobiological mechanisms of social anxiety disorder.

Authors:  S J Mathew; J D Coplan; J M Gorman
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

8.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Authors:  Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

9.  An open trial of topiramate in the treatment of generalized social phobia.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Pipe; Jonathan Oakman; Mark Bennett
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

Review 10.  Pharmacotherapy of generalized anxiety disorder.

Authors:  Karl Rickels; Moira Rynn
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

View more
  14 in total

1.  PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,+ exchange.

Authors:  Theresa V Nguyen; David E Smith; David Fleisher
Journal:  Pharm Res       Date:  2006-12-28       Impact factor: 4.200

Review 2.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

3.  Varying uses of anticonvulsant medications.

Authors:  Elisa Cascade; Amir H Kalali; Richard H Weisler
Journal:  Psychiatry (Edgmont)       Date:  2008-06

4.  Refractory social anxiety disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

Review 5.  Anxiety and medical disorders.

Authors:  Jacqueline E Muller; Liezl Koen; Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

6.  Combat posttraumatic stress disorder, substance use disorders, and traumatic brain injury.

Authors:  Kathleen T Brady; Peter Tuerk; Sudie E Back; Michael E Saladin; Angela E Waldrop; Hugh Myrick
Journal:  J Addict Med       Date:  2009-12       Impact factor: 3.702

7.  In vivo effects of glycyl-glutamate and glycyl-sarcosine on gabapentin oral absorption in rat.

Authors:  Theresa V Nguyen; David Fleisher; David E Smith
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.200

8.  Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats.

Authors:  Steffen Klein; Laurent B Nicolas; Cristina Lopez-Lopez; Laura H Jacobson; Silvia Gatti McArthur; Christophe Grundschober; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2010-06-01       Impact factor: 4.530

Review 9.  [Anticonvulsants in the treatment of anxiety--an alternative treatment option?].

Authors:  P Zwanzger; D Eser; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

10.  Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats.

Authors:  Laurent B Nicolas; Steffen Klein; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2007-06-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.